Atsushi Komaru

Chiba, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Generating Patient Documents from Electronic Health Records Using Generative Artificial Intelligence: A Feasibility Study in a Japanese Cancer Center.

Generating Patient Documents from Electronic Health Records Using Generative Artificial Intelligence: A Feasibility Study in a Japanese Cancer Center.

Journal: Applied clinical informatics

Published: July 20, 2026

Clinical Features and Prognostic Significance of Pulmonary Metastases in Metastatic Hormone-sensitive Prostate Cancer.

Clinical Features and Prognostic Significance of Pulmonary Metastases in Metastatic Hormone-sensitive Prostate Cancer.

Journal: Anticancer research

Published: March 17, 2026

A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.

A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.

Journal: The Prostate

Published: February 03, 2026

Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.

Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.

Journal: BJU international

Published: November 13, 2025

[177Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in Japan.

[177Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in Japan.

Journal: Cancers

Published: May 24, 2025

Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study.

Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study.

Journal: Japanese journal of clinical oncology

Published: March 26, 2025

Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer.

Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer.

Journal: Prostate international

Published: October 15, 2024

Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.

Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.

Journal: International journal of clinical oncology

Published: September 18, 2024

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis.

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis.

Journal: Cancer medicine

Published: July 09, 2024

Development and validation of novel nomogram to identify the candidates for extended pelvic lymph node dissection for prostate cancer patients in the robotic era.

Development and validation of novel nomogram to identify the candidates for extended pelvic lymph node dissection for prostate cancer patients in the robotic era.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: December 06, 2022

CLINICAL STUDY OF OPEN RADICAL CYSTECTOMY AND ILEAL CONDUIT CONSTRUCTION FOR BLADDER CANCER: RESULTS OF 15-YEAR SINGLE CENTER EXPERIENCE

CLINICAL STUDY OF OPEN RADICAL CYSTECTOMY AND ILEAL CONDUIT CONSTRUCTION FOR BLADDER CANCER: RESULTS OF 15-YEAR SINGLE CENTER EXPERIENCE

Journal: Nihon Hinyokika Gakkai zasshi. The japanese journal of urology

Published: January 01, 2021

Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.

Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.

Journal: The Prostate

Published: February 07, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026